Cite
HARVARD Citation
Pelosof, L. et al. (2021). Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy. Oncologist. pp. 318-324. [Online].